Literature DB >> 21275441

Cost effectiveness of rasagiline and pramipexole as treatment strategies in early Parkinson's disease in the UK setting: An economic Markov model evaluation.

Norbert Kovacs, Jozsef Janszky, Ferenc Nagy.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21275441     DOI： 10.2165/80-000000000-00000

Source DB:  PubMed          Journal:  Drugs Aging        ISSN： 1170-229X            Impact factor:   3.923


× No keyword cloud information.
  9 in total

1.  A controlled trial of rasagiline in early Parkinson disease: the TEMPO Study.

Authors: 
Journal:  Arch Neurol       Date:  2002-12

2.  A controlled, randomized, delayed-start study of rasagiline in early Parkinson disease.

Authors: 
Journal:  Arch Neurol       Date:  2004-04

Review 3.  Review of the therapeutic management of Parkinson's disease. Report of a joint task force of the European Federation of Neurological Societies and the Movement Disorder Society-European Section. Part I: early (uncomplicated) Parkinson's disease.

Authors:  M Horstink; E Tolosa; U Bonuccelli; G Deuschl; A Friedman; P Kanovsky; J P Larsen; A Lees; W Oertel; W Poewe; O Rascol; C Sampaio
Journal:  Eur J Neurol       Date:  2006-11       Impact factor: 6.089

4.  Pramipexole vs levodopa as initial treatment for Parkinson disease: A randomized controlled trial. Parkinson Study Group.

Authors: 
Journal:  JAMA       Date:  2000-10-18       Impact factor: 56.272

5.  Long-term outcome of early versus delayed rasagiline treatment in early Parkinson's disease.

Authors:  Robert A Hauser; Mark F Lew; Howard I Hurtig; William G Ondo; Joanne Wojcieszek; Cheryl J Fitzer-Attas
Journal:  Mov Disord       Date:  2009-03-15       Impact factor: 10.338

6.  Pramipexole vs levodopa as initial treatment for Parkinson disease: a 4-year randomized controlled trial.

Authors:  Robert G Holloway; Ira Shoulson; Stanley Fahn; Karl Kieburtz; Anthony Lang; Kenneth Marek; Michael McDermott; John Seibyl; William Weiner; Bruno Musch; Cornelia Kamp; Mickie Welsh; Aileen Shinaman; Rajesh Pahwa; Lynn Barclay; Jean Hubble; Peter LeWitt; Janis Miyasaki; Oksana Suchowersky; Mark Stacy; David S Russell; Blair Ford; John Hammerstad; David Riley; David Standaert; Frederick Wooten; Stewart Factor; Joseph Jankovic; Farah Atassi; Roger Kurlan; Michel Panisset; Ali Rajput; Robert Rodnitzky; Cliff Shults; Giselle Petsinger; Cheryl Waters; Ronald Pfeiffer; Kevin Biglan; Leona Borchert; Amy Montgomery; Laura Sutherland; Carolyn Weeks; Maryan DeAngelis; Elspeth Sime; Susan Wood; Carol Pantella; Mary Harrigan; Barbara Fussell; Sandra Dillon; Barbara Alexander-Brown; Pamela Rainey; Marsha Tennis; Elke Rost-Ruffner; Diane Brown; Sharon Evans; Debra Berry; Jean Hall; Theresa Shirley; Judith Dobson; Deborah Fontaine; Brenda Pfeiffer; Alicia Brocht; Susan Bennett; Susan Daigneault; Karen Hodgeman; Carolynn O'Connell; Tori Ross; Karen Richard; Arthur Watts
Journal:  Arch Neurol       Date:  2004-07

Review 7.  Monoamine oxidase B inhibitors versus other dopaminergic agents in early Parkinson's disease.

Authors:  Robert Caslake; Angus Macleod; Natalie Ives; Rebecca Stowe; Carl Counsell
Journal:  Cochrane Database Syst Rev       Date:  2009-10-07

8.  The clinically important difference on the unified Parkinson's disease rating scale.

Authors:  Lisa M Shulman; Ann L Gruber-Baldini; Karen E Anderson; Paul S Fishman; Stephen G Reich; William J Weiner
Journal:  Arch Neurol       Date:  2010-01

9.  Cost effectiveness of rasagiline and pramipexole as treatment strategies in early Parkinson's disease in the UK setting: an economic Markov model evaluation.

Authors:  Alan Haycox; Christophe Armand; Susana Murteira; John Cochran; Clément François
Journal:  Drugs Aging       Date:  2009       Impact factor: 3.923
  9 in total
  3 in total

Review 1.  Monoamine oxidase-B inhibitors in the treatment of Parkinson's disease: clinical-pharmacological aspects.

Authors:  Peter Riederer; Thomas Müller
Journal:  J Neural Transm (Vienna)       Date:  2018-03-22       Impact factor: 3.575

2.  Therapeutic strategies in the early stages of Parkinson's disease: a cross-sectional evaluation of 15 years' experience with a large cohort of Romanian patients.

Authors:  József Attila Szász; Károly Orbán-Kis; Viorelia Adelina Constantin; Csongor Péter; István Bíró; István Mihály; Kinga Szegedi; Antal Balla; Szabolcs Szatmári
Journal:  Neuropsychiatr Dis Treat       Date:  2019-04-05       Impact factor: 2.570

3.  An exercise intervention to prevent falls in Parkinson's: an economic evaluation.

Authors:  Emily Fletcher; Victoria A Goodwin; Suzanne H Richards; John L Campbell; Rod S Taylor
Journal:  BMC Health Serv Res       Date:  2012-11-23       Impact factor: 2.655
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.